Acne vulgaris. Acne vulgaris
Conditions
Interventions
Intervention 1: case: nano emulgel of spironolactone 1%, two times in day (BID) as topical, and for 2 months. Intervention 2: control: spironolactone gel 5%. The preparations will be administered topi
Treatment - Drugs
case: nano emulgel of spironolactone 1%, two times in day (BID) as topical, and for 2 months
control: spironolactone gel 5%. The preparations will be administered topically, two times in day and for two months
Sponsors
Vice chancellor of research
Eligibility
Sex/Gender
All
Age
11 Years to 45 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: patients with mild to moderate acne, defined as a score of 1 to 30 on the global acne grading system (GAGS) scale, who were not satisfied with their previous acne therapies participated in the study after giving written informed consent Exclusioncriteria: Patients were excluded if they had an uncontrolled systemic disease; had received topical antiacne therapy two months before or during the study or any systemic therapy with antibiotics, OCP, and spironolactone 30 days before or during the study; were known to be allergic or sensitive to any of the study medications or their components; had previously been treated with systemic retinoids; had a skin disease that might interfere with the diagnosis or evaluation of their hyperpigmentation; or were pregnant, or planning to become pregnant, and lactating.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Skin lesion. Timepoint: 0, 4, and 8 weeks. Method of measurement: observation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Sebum excretion. Timepoint: 0, 4, 8 weeks. Method of measurement: sebometer. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMajid Saeedi
Faculty of Pharmacy
Outcome results
None listed